Gregory A Nichols1, Anouk Déruaz-Luyet2, Sibylle J Hauske3, Kimberly G Brodovicz4. 1. Kaiser Permanente Center for Health Research, Portland, OR, USA. Electronic address: greg.nichols@kpchr.org. 2. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 3. Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany. 4. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Abstract
AIMS: We evaluated the simultaneous effects of all clinically recognized categories of albuminuria and estimated glomerular filtration rate (eGFR) on cardiovascular disease (CVD) and mortality METHODS: We conducted a longitudinal observational study of 16,678 type 2 diabetes (T2D) patients. From the first serum creatinine value from 2006 to 2012 and a urine-albumin creatinine ratio (UACR) recorded within 6months, we applied baseline Kidney Disease: Improving Global Outcomes (KDIGO) categories of eGFR and albuminuria. We followed patients for up to 11years to calculate adjusted incidence per 1000person-years (p-y) of first CVD hospitalization and all-cause mortality. RESULTS: Over 98,069p-y of follow-up, CVD hospitalization risk was greater for each higher eGFR and albuminuria category. In eGFR category G2 (60-89mL/min/1.73m2), adjusted incidence per 1000p-y was 14.1 (95% CI 12.9-15.5), 19.8 (17.2-22.8), and 22.8 (17.4-30.0) for normoalbuminuria, microalbuminuria and macroalbuminuria, respectively. For eGFR category G3a (45-59), rates were 26.7 (22.3-32.0), 40.3 (32.2-50.5), and 44.1 (28.8-67.4), respectively. Adjusted risk of all-cause mortality followed a similar pattern. CONCLUSIONS: Our data underscore the importance of including detailed eGFR and UACR values in assessing CVD risk. High albuminuria and low eGFR is a potent predictor of CVD and death.
AIMS: We evaluated the simultaneous effects of all clinically recognized categories of albuminuria and estimated glomerular filtration rate (eGFR) on cardiovascular disease (CVD) and mortality METHODS: We conducted a longitudinal observational study of 16,678 type 2 diabetes (T2D) patients. From the first serum creatinine value from 2006 to 2012 and a urine-albumin creatinine ratio (UACR) recorded within 6months, we applied baseline Kidney Disease: Improving Global Outcomes (KDIGO) categories of eGFR and albuminuria. We followed patients for up to 11years to calculate adjusted incidence per 1000person-years (p-y) of first CVD hospitalization and all-cause mortality. RESULTS: Over 98,069p-y of follow-up, CVD hospitalization risk was greater for each higher eGFR and albuminuria category. In eGFR category G2 (60-89mL/min/1.73m2), adjusted incidence per 1000p-y was 14.1 (95% CI 12.9-15.5), 19.8 (17.2-22.8), and 22.8 (17.4-30.0) for normoalbuminuria, microalbuminuria and macroalbuminuria, respectively. For eGFR category G3a (45-59), rates were 26.7 (22.3-32.0), 40.3 (32.2-50.5), and 44.1 (28.8-67.4), respectively. Adjusted risk of all-cause mortality followed a similar pattern. CONCLUSIONS: Our data underscore the importance of including detailed eGFR and UACR values in assessing CVD risk. High albuminuria and low eGFR is a potent predictor of CVD and death.
Authors: Eugenia Wong; Shoshana H Ballew; Natalie Daya; Junichi Ishigami; Casey M Rebholz; Kunihiro Matsushita; Morgan E Grams; Josef Coresh Journal: Am J Nephrol Date: 2019-07-16 Impact factor: 3.754
Authors: Joshua I Barzilay; Petra Buzkova; Michael G Shlipak; Nisha Bansal; Pranav Garimella; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Tarunveer S Ahluwalia; Christina-Alexandra Schulz; Johannes Waage; Tea Skaaby; Niina Sandholm; Natalie van Zuydam; Romain Charmet; Jette Bork-Jensen; Peter Almgren; Betina H Thuesen; Mathilda Bedin; Ivan Brandslund; Cramer K Christensen; Allan Linneberg; Emma Ahlqvist; Per-Henrik Groop; Samy Hadjadj; David-Alexandre Tregouet; Marit E Jørgensen; Niels Grarup; Oluf Pedersen; Matias Simons; Leif Groop; Marju Orho-Melander; Mark I McCarthy; Olle Melander; Peter Rossing; Tuomas O Kilpeläinen; Torben Hansen Journal: Diabetologia Date: 2018-12-13 Impact factor: 10.122
Authors: Charumathi Sabanayagam; Miao Li Chee; Riswana Banu; Ching-Yu Cheng; Su Chi Lim; E Shyong Tai; Thomas Coffman; Tien Y Wong Journal: JAMA Netw Open Date: 2019-03-01
Authors: Ofri Mosenzon; Stephen C Bain; Hiddo J L Heerspink; Thomas Idorn; Johannes F E Mann; Frederik Persson; Richard E Pratley; Søren Rasmussen; Peter Rossing; Bernt Johan von Scholten; Itamar Raz Journal: Diabetes Obes Metab Date: 2020-08-07 Impact factor: 6.577